Department of Pharmacodynamic, Laboratory of Pharmacological Screening, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
Naunyn Schmiedebergs Arch Pharmacol. 2011 Jan;383(1):13-25. doi: 10.1007/s00210-010-0566-x. Epub 2010 Oct 15.
A series of novel pyrrolidin-2-one derivatives (17 compounds) with adrenolytic properties was evaluated for antiarrhythmic, electrocardiographic and antioxidant activity. Some of them displayed antiarrhythmic activity in barium chloride-induced arrhythmia and in the rat coronary artery ligation-reperfusion model, and slightly decreased the heart rate, prolonged P-Q, Q-T intervals and QRS complex. Among them, compound EP-40 (1-[2-hydroxy-3-[4-[(2-hydroxyphenyl)piperazin-1-yl]propyl]pyrrolidin-2-one showed excellent antiarrhythmic activity. This compound had significantly antioxidant effect, too. The present results suggest that the antiarrhythmic effect of compound EP-40 is related to their adrenolytic and antioxidant properties. A biological activity prediction using the PASS software shows that compound EP-35 and EP-40 can be characterized by antiischemic activity; whereas, compound EP-68, EP-70, EP-71 could be good tachycardia agents.
一系列具有肾上腺能拮抗作用的新型吡咯烷-2-酮衍生物(17 种化合物),其抗心律失常、心电图和抗氧化活性进行了评价。其中一些化合物在氯化钡诱导的心律失常和大鼠冠状动脉结扎再灌注模型中表现出抗心律失常活性,并且略微降低了心率,延长了 P-Q、Q-T 间隔和 QRS 复合物。其中,化合物 EP-40(1-[2-羟基-3-[4-[(2-羟基苯基)哌嗪-1-基]丙基]吡咯烷-2-酮表现出优异的抗心律失常活性。该化合物还具有显著的抗氧化作用。目前的结果表明,化合物 EP-40 的抗心律失常作用与其肾上腺能拮抗和抗氧化特性有关。使用 PASS 软件进行的生物活性预测表明,化合物 EP-35 和 EP-40 可以具有抗缺血活性的特征;而化合物 EP-68、EP-70、EP-71 可能是良好的心动过速药物。